Digestive Dysbiosis in Systemic Scleroderma: a Review

1. McMahan ZH, Hummers LK. Gastrointestinal involvement in systemic sclerosis: diagnosis and management. Curr Opin Rheumatol. 2018;30:533-540.10.1097/BOR.000000000000054530234725Search in Google Scholar

2. Denaxas K, Ladas SD, Karamanolis GP. Evaluation and management of esophageal manifestations in systemic sclerosis. Ann Gastroenterol. 2018;31:1-6.10.20524/aog.2018.0228582594629507463Search in Google Scholar

3. Tétreault MP, Kahrilas P. GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis. Curr Rheumatol Rep. 2019;21;42.10.1007/s11926-019-0841-x885283831270707Search in Google Scholar

4. Miller JB, Gandhi N, Clarke J, McMahan Z. Gastrointestinal Involvement in Systemic Sclerosis: An Update. J Clin Rheumatol. 2018;24:328-337.10.1097/RHU.0000000000000626611037729095721Search in Google Scholar

5. Schmeiser T, Saar P, Jin D, et al. Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatol Int. 2012;32:2471-2478.10.1007/s00296-011-1988-621769490Search in Google Scholar

6. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clinic Rev Allerg Immunol. 2017;53:306-336.10.1007/s12016-017-8625-428712039Search in Google Scholar

7. Anton E. Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol. 2016;13:461-472.10.1038/nrgastro.2016.9927381075Search in Google Scholar

8. Lynch S, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016;375:2369-2379.10.1056/NEJMra160026627974040Search in Google Scholar

9. Vogelzang A, Guerrini MM, Minato N, Fagarasan S. Microbiota – an amplifier of autoimmunity. Curr Opin Immunol. 2018;55:15-21.10.1016/j.coi.2018.09.00330248521Search in Google Scholar

10. Tallota R, Atzeni F, Ditto MC, Gerardi MC, Sarzi-Puttini P. The Microbiome in Connective Tissue Diseases and Vasculitides: An Update Narrative Review. J Immunol Res. 2017; 2017:6836498.10.1155/2017/6836498555660928835902Search in Google Scholar

11. Tong Y, Marion T, Schett G, Luo Y, Liu Y. Microbiota and metabolites in rheumatic diseases. Autoimmun Rev. 2020;19:102530.10.1016/j.autrev.2020.102530Search in Google Scholar

12. Konig MF. The microbiome in autoimmune rheumatic disease. Best Pract Res Clin Rheumatol. 2020;34:101473.10.1016/j.berh.2019.101473Search in Google Scholar

13. Asano Y. The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies. J Clin Med. 2020;9:2687.10.3390/jcm9092687Search in Google Scholar

14. Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. Semin Arthritis Rheum. 2016;46:115-123.10.1016/j.semarthrit.2016.02.005Search in Google Scholar

15. Smirani R, Poursac N, Naveau A, Schaeverbeke T, Devillard R, Truchetet ME. Orofacial consequences of systemic sclerosis: A systematic review. J Scleroderma Relat Disord. 2018;3:88-90.10.1177/2397198317746966Search in Google Scholar

16. Hadj Said M, Foletti J, Graillon N, Guyot L, Chossegros C. Orofacial manifestations of scleroderma. A literature review. Rev Stomatol Chir Maxillofac Chir Orale. 2016;117:322-326.Search in Google Scholar

17. Jung S, Martin T, Schmittbuhl M, Huck O. The spectrum of orofacial manifestations in systemic sclerosis: a challenging management. Oral Dis. 2017;23:424-439.10.1111/odi.12507Search in Google Scholar

18. Gomes da Silva G, Maymone de Melo M, Leão J, et al. Oral features of systemic sclerosis: A case control study. Oral Dis. 2019;25:1995-2002.10.1111/odi.13174Search in Google Scholar

19. Baron M, Hudson M, Tatibouet S, et al. The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. Rheumatology (Oxford). 2014;53:1386-1394.10.1093/rheumatology/ket441Search in Google Scholar

20. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005;366:1809-1820.10.1016/S0140-6736(05)67728-8Search in Google Scholar

21. Isola G, Williams RC, Lo Gullo A, et al. Risk association between scleroderma disease characteristics, periodontitis, and tooth loss. Clin Rheumatol. 2017;36:2733-2741.10.1007/s10067-017-3861-928988297Search in Google Scholar

22. Cheng Z, Meade J, Mankia K, Emery P, Devine DA. Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017;31:1-12.10.1016/j.berh.2017.08.00129221594Search in Google Scholar

23. Kobak S, Oskel F, Aksu K, Kabasakal Y. The frequency of sicca symptoms and Sjogren’s syndrome in patients with systemic sclerosis. Int J Rheum Dis. 2013;16:88-92.10.1111/j.1756-185X.2012.01810.x23441777Search in Google Scholar

24. Denaxas K, Ladas SD, Karamanolis GP. Evaluation and management of esophageal manifestations in systemic sclerosis. Ann Gastroenterol. 2018;31:165-170.10.20524/aog.2018.0228582594629507463Search in Google Scholar

25. Roberts CGP, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55:1697-1703.10.1136/gut.2005.086074185646216527835Search in Google Scholar

26. Kumar S, Singh J, Rattan S, DiMarino A, Cohen S, Jimenez S. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. Aliment Pharmacol Ther. 2017;45:883-898.10.1111/apt.13963557644828185291Search in Google Scholar

27. Lee JS, Kim HS, Moon JR, et al. Esophageal involvement and Determinants of Perception of Esophageal Symptoms Among South Koreans With Systemic Sclerosis. J Neurogastroenterol Motil. 2020;26:477-485.10.5056/jnm19148754719632989185Search in Google Scholar

28. Arana-Guajardo AC, Barrera-Torres G, Villarreal-Alarcón MÁ, Vega-Morales D, Esquivel-Valerio JA. Esophageal symptoms and their lack of association with high-resolution manometry in systemic sclerosis patients. Reumatol Clin. 2017;15:165-169.10.1016/j.reuma.2017.09.00529258795Search in Google Scholar

29. Crowell MD, Umar SB, Griffing LW, DiBase JK, Lacy BE, Vela MF. Esophageal Motor Abnormalities in Patients With Scleroderma: Heterogeneity, Risk Factors, and Effects on Quality of Life. Clin Gastroenterol Hepatol. 2017;15:207-213.10.1016/j.cgh.2016.08.03427613260Search in Google Scholar

30. De Carlan M, Lescoat A, Brochard C, et al. Association between clinical manifestations of systemic sclerosis and esophageal dysmotility assessed by high-resolution manometry. J Scleroderma Relat Disord. 2017;2:50-56.10.5301/jsrd.5000233Search in Google Scholar

31. Nicola S, Rolla G, Bucca C, et al. Gastric Juice Expression of Th-17 and T-Reg Related Cytokines in Scleroderma Esophageal Involvement. Cells. 2020;19;2106.10.3390/cells9092106756448032947843Search in Google Scholar

32. Snyder DL, Crowell MD, Kahn A, Griffing WL, Umar S, Ramirez FC. Prevalence of Barrett’s Esophagus in Female Patients With Scleroderma. Am J Gastroenterol. 2020;116:517-521.10.14309/ajg.000000000000110933657040Search in Google Scholar

33. Petcu A, Ghib LJ, Grad SM, et al. Upper gastrointestinal involvement in systemic sclerosis: Findings in a real-life setting. Exp Ther Med. 2019;18:5095-5100.10.3892/etm.2019.8125688039531798729Search in Google Scholar

34. Grusell NE, Dahlén G, Ruth M, et al. Bacterial flora of the human oral cavity, and the upper and lower esophagus. Dis Esophagus. 2012;53:650-656.Search in Google Scholar

35. D’Souza SM, Cundra LB, Yoo BS, Parekh PJ, Johnson DA. Microbiome and Gastroesophageal Disease: Pathogenesis and Implications for Therapy. Ann Clin Gastroenterol Hepatol. 2020;4:020-033.10.29328/journal.acgh.1001018Search in Google Scholar

36. Espinoza M, Mehta BK, Wang Y, et al. Characterization of the Esophageal Microbiome in Patients with Systemic Sclerosis (SSc). Arthritis Rheumatol. 2018;Suppl70.Search in Google Scholar

37. Hong BY, Giang R, Mbuagbaw L, Larche M, Thabane L. Factors associated with development of gastrointestinal problems in patients with scleroderma: a systematic review. Syst Rev. 2015;4:188.10.1186/s13643-015-0176-2469731826718896Search in Google Scholar

38. Radić M. Role of Helicobacter pylori infection in autoimmune systemic rheumatic diseases. World J Gastroenterol. 2014;20:12839-12846.10.3748/wjg.v20.i36.12839417746625278681Search in Google Scholar

39. Yong W, Upala S, Sanguankeo A. Helicobacter pylori infection in systemic sclerosis: a systematic review and meta-analysis of observational studies. Clin Exp Rheumatol. 2018;36(Suppl.113): S168-S174.Search in Google Scholar

40. Radić M, Kaliterna MD, Bonacin D, et al. Is Helicobacter pylori infection a risk factor for disease severity in systemic sclerosis? Rheumatol Int. 2013;33:2943-2948.Search in Google Scholar

41. Yamaguchi K, Iwakiri R, Hara M, et al. Reflux Esophagitis and Helicobacter pylori Infection in Patients with Scleroderma. Inter Med. 2008;47:1555-1559.10.2169/internalmedicine.47.112818797112Search in Google Scholar

42. Ram M, Barzilai O, Shapira Y, et al. Helicobacter pylori serology in autoimmune diseases: fact or fiction? Clin Chem Lab Med. 2013;51:1075-1082.Search in Google Scholar

43. Bilgin H, Kocabaș H, Keșli R. The prevalence of infectious agents in patients with systemic sclerosis. Turk J Med Sci. 2015;45:1192-1197.10.3906/sag-1404-150Search in Google Scholar

44. Balaji C, Bhuvanesh M, Saranya C, Ramesh R, Saravanan M, Rajeswari S. Helicobacter Pylori infection in Systemic Sclerosis and Its Association with Upper Gastrointestinal Dysfunction. Indian J Rheumatol. 2017;12:204-208.10.4103/injr.injr_62_17Search in Google Scholar

45. Efthymiou G, Liaskos C, Siamopoulou T, et al. Antigen-specific humoral responses against Helicobacter pylori in patients with systemic sclerosis. Immunol Res. 2020;68:39-47.10.1007/s12026-020-09124-w32253703Search in Google Scholar

46. Quigley EM. Small Intestinal Dysmotility, Its Role in Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth: Assessment and Management. Front Gastrointest Res Basel Karger. 2014;33:55-64.10.1159/000356743Search in Google Scholar

47. Rawn S, Pitman N, Beattie K, Bazzaz A, Larche M. Small Intestinal Bacterial Overgrowth in Patients with Systemic Sclerosis. Indian J Rheumatol. 2017;12:S167-S170.10.4103/0973-3698.219077Search in Google Scholar

48. Feng X, Li XQ, Jiang Z. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol. 2021 January. [Epub ahead of print]10.1007/s10067-020-05549-833426631Search in Google Scholar

49. Marie I, Ducrotté P, Denis P, Menard JF, Levesque H. Small Intestinal bacterial overgrowth in systemic sclerosis. Rheumatology. 2009;48:1314-1319.10.1093/rheumatology/kep22619696066Search in Google Scholar

50. Polkowska-Pruszyńska B, Gerkowicz A, Rawicz-Pruszyński K, Krasowska D. The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO). Diagnostics. 2020;10:587.10.3390/diagnostics10080587745988232823752Search in Google Scholar

51. Preis E, Franz K, Siegert E, et al. The impact of malnutrition on quality of life in patients with systemic sclerosis. Eur J Clin Nutr. 2018;72:504-510.10.1038/s41430-018-0116-z29520082Search in Google Scholar

52. Zou H, De Palma G, Bercik P, Verdu E, Beattie K, Larche M. Distinct Characteristics of the Gut Microbiome of Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth [abstract]. Arthritis Rheumatol. 2019;71(suppl10).Search in Google Scholar

53. Parodi A, Sessarego M, Greco A, et al. Small Intestinal Bacterial Overgrowth in Patients Suffering From Scleroderma: Clinical Effectiveness of Its Eradication. Am J Gastroenetrol. 2008;103: 1257-1262.10.1111/j.1572-0241.2007.01758.x18422815Search in Google Scholar

54. Fynne L, Worsøe J, Gregersen T, Schalageter V, Laurberg S, Krogh K. Gastrointestinal transit in patients with systemic sclerosis. Scand J Gastroenterol. 2011;46:1187-1193.10.3109/00365521.2011.60315821815862Search in Google Scholar

55. Gemignani L, Savarino V, Ghio M, et al. Lactulose Breath Test to Assess Orocecal Transit Delay and Estimate Esophageal Dysmotility in Scleroderma Patients. Semin Arthritis Rheum. 2013;42:522-529.10.1016/j.semarthrit.2012.09.00423352249Search in Google Scholar

56. Savarino E, Mei F, Parodi A, et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology. 2013;52:1095-1100.10.1093/rheumatology/kes42923382360Search in Google Scholar

57. Tauber M, Avouac J, Benahmed A, et al. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol. 2014;32:S82-S87.Search in Google Scholar

58. Soukup T, Cyrany J, Kopacova M, Tacheci I, Bures J. Small intestinal bacterial overgrowth in patients with systemic sclerosis, clinical data relevance [abstract]. Clin and Exp Rheumatol. 2014;32:S132.Search in Google Scholar

59. Marie I, Leroi A, Menard J, Levesque H, Quillard M, Ducrotte P. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev. 2015;14:547-554.10.1016/j.autrev.2015.01.01825661980Search in Google Scholar

60. Adarsh M, Sharma S, Sinha S, et al. Gastrointestinal Dysmotility and Infections in Systemic Sclerosis – An Indian Scenario. Curr Rheumatol Rev. 2017;13.Search in Google Scholar

61. Cruz-Dominguez M, Garcia-Collinot G, Madrigal-Santillan E, et al. Small intestinal bacterial overgrowth in relation to gastrointestinal symptoms in systemic sclerosis [abstract]. Ann Rheum Dis. 2017;103:1282.Search in Google Scholar

62. Sawadpanich K, Soison P, Chunlertrith K, et al. Prevalence and associated factors of small intestinal bacterial overgrowth among systemic sclerosis patients. Int J Rheum Dis. 2019;22:695-699.10.1111/1756-185X.1349530729669Search in Google Scholar

63. García-Collinot G, Madrigal-Santillán EO, Martínez-Benzomo MA, et al. Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Dig Dis Sci. 2020;65:1134-1143.10.1007/s10620-019-05830-031549334Search in Google Scholar

64. Zhang X, Chen Bd, Zhao Ld, Li H. The Gut Microbiota: Emerging Evidence in Autoimmune Diseases. Trends Mol Med. 2020;26:862-873.10.1016/j.molmed.2020.04.00132402849Search in Google Scholar

65. Volkmann E, Chang Y, Barroso N, et al. Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium. Arthritis Rheumatol. 2016;68:1483-1492.10.1002/art.39572556166626749064Search in Google Scholar

66. Andrnasson K, Alrawi Z, Persson A, Jonsson G, Marsal J. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res Ther. 2016;18:278.10.1186/s13075-016-1182-z512698627894337Search in Google Scholar

67. Bosello S, Paroni Sterbini F, Natalello G, et al. The intestinal involvement in systemic sclerosis is characterized by a peculiar gut microbiota [abstract]. Arthritis Rheumatol. 2016;68.Search in Google Scholar

68. Volkmann E, Hoffman-Vold A, Chang Y, et al. Systemic sclerosis is associated with alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol. 2017;4: e000134.10.1136/bmjgast-2017-000134550863628761687Search in Google Scholar

69. Patrone V, Puglisi E, Cardinali M, et al. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. Sci Rep. 2017;7:14874.10.1038/s41598-017-14889-6566591229093509Search in Google Scholar

70. Bellocchi C, Fernandez-Ochoa A, Montanelli G, et al. Microbial and metabolic multi-omic correlations in systemic sclerosis patients. Ann N Y Acad Sci. 2018;1421:97-109.10.1111/nyas.1373629749635Search in Google Scholar

71. Natalello G, Bosello S, Paroni Sterbini F, et al. Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status. Clin Exp Rheumatol. 2020;38(Suppl. 125).Search in Google Scholar

72. Bellocchi C, Volkmann ER. Update on the Gastrointestinal Microbiome in Systemic Sclerosis. Curr Rheumatol Rep. 2018;20:49.10.1007/s11926-018-0758-929943234Search in Google Scholar